These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 18570606

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Moxifloxacin: a respiratory fluoroquinolone.
    Miravitlles M, Anzueto A.
    Expert Opin Pharmacother; 2008 Jul; 9(10):1755-72. PubMed ID: 18570608
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Comparative analysis of length of stay, total costs, and treatment success between intravenous moxifloxacin 400 mg and levofloxacin 750 mg among hospitalized patients with community-acquired pneumonia.
    Friedman H, Song X, Crespi S, Navaratnam P.
    Value Health; 2009 Jul; 12(8):1135-43. PubMed ID: 19695010
    [Abstract] [Full Text] [Related]

  • 7. Moxifloxacin in respiratory tract infections.
    Miravitlles M.
    Expert Opin Pharmacother; 2005 Feb; 6(2):283-93. PubMed ID: 15757424
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Moxifloxacin (Avelox): an 8-methoxyquinolone antibacterial with enhanced potency.
    Ball P.
    Int J Clin Pract; 2000 Jun; 54(5):329-32. PubMed ID: 10954961
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Clinical perspectives on new antimicrobials: focus on fluoroquinolones.
    Talan DA.
    Clin Infect Dis; 2001 Mar 15; 32 Suppl 1():S64-71. PubMed ID: 11249831
    [Abstract] [Full Text] [Related]

  • 12. Moxifloxacin: new indication. Inadequate restriction of indications in ENT and respiratory infections.
    Prescrire Int; 2009 Oct 15; 18(103):206. PubMed ID: 19882787
    [Abstract] [Full Text] [Related]

  • 13. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment.
    Pfaller MA, Ehrhardt AF, Jones RN.
    Am J Med; 2001 Dec 17; 111 Suppl 9A():4S-12S; discussion 36S-38S. PubMed ID: 11755437
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Moxifloxacin--a new fluoroquinolone antibacterial.
    Drug Ther Bull; 2004 Aug 17; 42(8):61-2. PubMed ID: 15310155
    [Abstract] [Full Text] [Related]

  • 16. An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia.
    Drummond MF, Becker DL, Hux M, Chancellor JV, Duprat-Lomon I, Kubin R, Sagnier PP.
    Chest; 2003 Aug 17; 124(2):526-35. PubMed ID: 12907538
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.